Drug intelligence / Profile preview

NOBO-501

Development stage: Preclinical
Lead developer: NOBO Medicine
Modality: Small Molecules

Overview

NOBO-501 is a small molecule inhibitor developed by NOBO Medicine that specifically targets the JAK2 V617F mutation. This mutation is a well-characterized driver of myeloproliferative neoplasms (MPNs) and is associated with various hematological inflammatory conditions. Developed as part of the company's proprietary NOBO-VERSE platform, NOBO-501 is designed to selectively inhibit the aberrant signaling pathways triggered by the mutated JAK2 kinase. The drug is currently in the discovery and preclinical stages of development, with a primary focus on treating hemato-inflammation.

Targets

JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on NOBO-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOBO-501.

Explore the full profile